# Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

> **NCT01590615** · — · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 54 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Anti-HBV nucleoside/nucleotide therapy

## Key facts

- **NCT ID:** NCT01590615
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-26
- **Primary completion:** 2017-04-04
- **Final completion:** 2017-04-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590615, "Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01590615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*